Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 3/20 | 0.46 |
| ▸ | CDC7 | O00311 | 4/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | EEF2K | O00418 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30095833 | 1.00 | LIMK1 (0.46) | LIMK1CDC7DBF4ACHEMEN1 | |
| SCHEMBL9433906 | 0.95 | LIMK1 (0.46) | LIMK1CDC7DBF4ACHEMEN1 | |
| SCHEMBL4195565 | 0.77 | DYRK1A (0.35) | LIMK1DYRK1A | |
| SCHEMBL31065827 | 0.77 | PNMT (0.34) | LIMK1CDC7DBF4NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL30170812 | 0.75 | DYRK1A (0.34) | LIMK1DYRK1A | |
| SCHEMBL192283 | 0.73 | TSHR (0.41) | LIMK1ACHEMEN1MAPK1KMT2A | |
| SCHEMBL1586120 | 0.73 | DRD1 (0.48) | CDC7DBF4MEN1MAPK1KMT2A | |
| SCHEMBL191834 | 0.73 | TSHR (0.37) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL30350551 | 0.73 | TSHR (0.41) | LIMK1ACHEMEN1MAPK1KMT2A | |
| SCHEMBL28820664 | 0.72 | ALDH1A1 (0.50) | LIMK1CDC7DBF4ACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025102016-A1 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025102016-A1 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022240876-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140336382-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
| EP-2593461-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009309-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-2049501-B1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | LIMK1 266/4885CDC7 484/4885DBF4 1578/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | LIMK1 266/4885CDC7 484/4885DBF4 1578/4885 |
| US-20140323464-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | LIMK1 472/4885CDC7 57/4885DBF4 1622/4885 |
| US-20140336382-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | LIMK1 132/4885CDC7 1795/4885DBF4 1342/4885 |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | LIMK1 266/4885CDC7 484/4885DBF4 1578/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | LIMK1 266/4885CDC7 484/4885DBF4 1578/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | LIMK1 279/4885CDC7 471/4885DBF4 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.